A PHASE II CLINICAL STUDY OF BBI503 IN ADULT PATIENTS WITH ADVANCED HEPATOBILIARY CANCER
- Registry ID
- BBI503-205B
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- SUMITOMO DAINIPPON PHARMA ONCOLOGY INC
- Start date
- 2015-08-12
- Completion date
- 2021-09-03
- Last update
- 2014-04-28
Conditions
- BILIARY CANCER
- HEPATOCELLULAR CARCINOMA
Related clinical trials
- PHASE III, RANDOMIZED, OPEN-LABEL, GLOBAL, MULTICENTER STUDY OF RILVEGOSTOMIG OR DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (ARTEMIDE-BILIARY02)
- RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AND TREMELIMUMAB AND
SURGERY VERSUS RADIATION THERAPY FOLLOWED BY SURGERY FOR RESECTABLE
HEPATOCELLULAR CARCINOMA. A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL
(DARTS)
- A MULTICENTER, OPEN LABEL, NON-RANDOMIZED FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF BAY 3547926 ALONE, AND IN COMBINATION, IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
- BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE
TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
- PERIOPERATIVE THERAPY WITH DURVALUMAB PLUS TREMELIMUMAB FOR PATIENTS WITH RESECTABLE HEPATOCELLULAR CARCINOMA (HCC) - A PHASE II TRIAL (NEOTOMA)
- ATEZOLIZUMAB AND BEVACIZUMAB PRE-LIVER TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA BEYOND MILAN CRITERIA: A FEASIBILITY STUDY
View on source registry